SignPath Pharma (www.signpathpharma.com) is a clinical stage biotechnology company (Delaware C Corp.) founded in 2006. Currently, SignPath is actively developing products to treat cancer and mitigate drug-induced cardiac arrhythmia, which is a serious and common side effect of many drugs, and heart muscle damage caused by chemotherapy.
Looking for a particular SignPath Pharma Inc. employee's phone or email?
The SignPath Pharma Inc. annual revenue was $23000 in 2026.
Kai Larson is the President and CEO of SignPath Pharma Inc..
5 people are employed at SignPath Pharma Inc..
SignPath Pharma Inc. is based in Sandy, Utah.
The NAICS codes for SignPath Pharma Inc. are [325, 3254, 32541, 32].
The SIC codes for SignPath Pharma Inc. are [283, 28].